Gastrointestinal stromal tumor

GIST most often starts in the stomach or small intestine, but can occur elsewhere in the digestive tract. It may be found incidentally or cause bleeding, anemia, abdominal discomfort, early fullness or obstruction. Vomiting blood, black stools with faintness, or sudden severe abdominal pain need urgent assessment.

CT or MRI defines the mass and possible spread; endoscopic ultrasound can assess a lesion arising within the gut wall. Pathology combines cell appearance with markers such as KIT/CD117 and DOG1. When tissue is needed, a planned core biopsy should provide enough material for diagnosis and molecular analysis while minimizing rupture or spillage.

An immediately resectable tumor with convincing features may proceed to surgery without a preoperative biopsy, whereas drug treatment before surgery requires tissue confirmation and mutation testing. The team should explain which pathway fits the anatomy and treatment plan.

Molecular testing identifies the driver and sometimes explains drug resistance before treatment starts. Most KIT-mutant GISTs are sensitive to imatinib, but the exon and variant matter. PDGFRA D842V is resistant to imatinib; other PDGFRA variants should not automatically be grouped with D842V.

“KIT/PDGFRA wild-type” means those common drivers were not found, not that there is no molecular explanation. Further work may include SDHB staining and assessment for SDH deficiency, NF1, BRAF or rare fusions. In selected patients, germline testing and genetic counseling address inherited risk; tumor sequencing alone does not establish a hereditary diagnosis.

Risk assessment uses tumor size, original site and mitotic count, together with rupture. A small gastric GIST and a similar-sized small-bowel GIST can have different risks. The pathology report should state the area used to count mitoses; a number without its measurement area is difficult to interpret. Surgical margins and rupture are separate issues.

True rupture before or during surgery carries a particularly high risk of peritoneal relapse. The April 2026 Onkopedia update specifically revisits this situation. The operation record should be reviewed against a formal rupture definition; microscopic margin involvement is not automatically rupture. An imatinib-sensitive ruptured tumor needs discussion of prolonged systemic treatment rather than an automatic stop at a routine adjuvant milestone.

Localized GIST is generally treated by complete removal without disrupting the tumor capsule. Routine wide lymph-node dissection, as used for some stomach cancers, is usually unnecessary; suspicious nodes and SDH-deficient disease require separate consideration. The operation should preserve function where possible without accepting avoidable tumor spillage.

Selected small gastric lesions may be monitored with endoscopy or endoscopic ultrasound instead of immediate removal. This depends on size, growth, symptoms and concerning imaging features, as well as the reliability of the diagnosis and follow-up. A small lesion in another location should not automatically follow the same observation plan.

For an imatinib-sensitive GIST where immediate surgery would be extensive or risky, preoperative imatinib may shrink the tumor and improve the chance of a function-preserving resection. This can matter near the rectum, duodenum or gastroesophageal junction. Confirm the mutation first and plan early response assessment; an insensitive tumor should not lose time on an ineffective drug.

The team follows response until an appropriate surgical opportunity, rather than prescribing a fixed duration for everyone. Baseline size, mitotic information obtained before treatment and rupture history remain important when planning postoperative therapy because treatment can alter the resection specimen.

High-risk, imatinib-sensitive GIST is the main setting for adjuvant imatinib. Three years has established long-term evidence: SSGXVIII/AIO showed better recurrence-free and overall survival than one year. This does not mean every completely removed GIST needs treatment, and insensitive molecular subtypes should not receive imatinib simply because their estimated risk is high.

IMADGIST subsequently randomized patients who had already received three years of adjuvant imatinib to stop or continue for three additional years. Six years improved disease-free survival; an overall-survival advantage was not established in the reported analysis. Extended treatment is therefore a specific discussion for sufficiently high-risk, sensitive disease, considering tolerability, patient preference and the uncertainty about the ideal duration.

For most imatinib-sensitive unresectable or metastatic GIST, imatinib is the first systemic treatment. KIT exon 9 can affect the specialist’s dose choice in advanced disease; the higher-dose evidence should not be automatically transferred to the postoperative setting. Blood tests, interactions, adherence and side effects are part of treatment assessment, not administrative details.

BFR14 demonstrated that stopping imatinib in controlled advanced disease often leads to rapid progression, even after years of response. Its long-term follow-up reinforces continued treatment when effective and tolerable. This differs from stopping after a planned adjuvant course following curative surgery. Any interruption for toxicity should be coordinated with the treating team.

CT response is not measured by diameter alone. A treated lesion can become less dense before shrinking, while a new growing nodule within a mass can indicate resistance. Interpretation by a team familiar with GIST helps avoid stopping an effective drug or overlooking real progression.

Avapritinib provides a distinct pathway for PDGFRA D842V-mutant advanced GIST. The US label covers adults with unresectable or metastatic PDGFRA exon 18-mutant GIST, including D842V; the EU GIST indication specifically names D842V. Approval for advanced disease is not proof of routine benefit as postoperative adjuvant therapy.

SDH-deficient GIST has different biology and may occur in younger patients, with multifocal tumors or lymph-node involvement. It often responds poorly to imatinib. Expert review, appropriate surgery, genetics and a subtype-focused trial discussion are important; conventional risk calculators may not predict its course reliably. The PEMIGIST phase II trial is studying pemigatinib in advanced SDH-deficient GIST, not establishing it as routine treatment.

Before labeling a tumor resistant, review missed doses, interacting medicines, dose reductions and the scan pattern. A relapse after completing adjuvant imatinib is not automatically equivalent to progression while taking it. If only one or a few sites escape control, selected surgery or ablation may be discussed while maintaining systemic control; widespread progression usually needs a systemic change.

The established sequence after imatinib generally uses sunitinib, then regorafenib, then ripretinib, with molecular subtype, intolerance and local labels affecting individual choices. A specialist may consider imatinib dose escalation in selected cases. These medicines have different resistance coverage and toxicity profiles; they are not interchangeable simply because all are kinase inhibitors.

INTRIGUE did not establish ripretinib as superior to sunitinib for the overall second-line population, and its final survival analysis did not establish an overall-survival advantage. Exploratory mutation subgroups are useful for research but should not be presented as proof that every patient should skip the established second-line option.

The phase III PEAK results reported at ASCO in 2026 showed that bezuclastinib plus sunitinib prolonged median progression-free survival compared with sunitinib alone after imatinib: 16.5 versus 9.2 months. Liver-enzyme elevations and other adverse effects require attention. A progression-free survival result should not be described as proof of cure or a confirmed overall-survival gain.

The combination’s US application has been accepted for priority review, with a target decision date of November 30, 2026, according to the sponsor. At this page’s update it remains under review. Trial or expanded-access routes have eligibility and location restrictions; an accepted application is not a marketing authorization.

INSIGHT tests whether ripretinib is preferable for a narrowly defined KIT exon 11 plus 17/18 resistance pattern. Velzatinib (IDRX-42) is also being developed through the StrateGIST program. These approaches illustrate why an up-to-date mutation profile can matter, but investigational drugs and exploratory biomarker results should remain clearly separated from established treatment.

Surveillance after surgery is adapted to recurrence risk and treatment history, usually emphasizing abdominal and pelvic imaging. Follow-up often becomes closer around stopping adjuvant therapy. In advanced disease, scans assess both response and new sites while laboratory and clinical checks assess safety. The schedule should be written down rather than inferred from how well a person feels.

Report persistent swelling, diarrhea, painful hand–foot changes, unusual bleeding or symptoms of liver problems. Avapritinib also requires attention to cognitive changes and intracranial bleeding risk: new confusion or a severe headache needs prompt medical assessment. Dose changes can preserve treatment tolerability, but should be directed by the treating team.

Prepare the original pathology with mitotic count and rupture details, the exact KIT/PDGFRA or other molecular result, baseline and recent scans, surgery records, and every targeted drug’s dose, duration, response and reason for stopping. The most useful review explains what changes the next decision, not just which drug name comes next.